Current Topics in Behavioral Neurosciences
December 31, 2024
Mazdak M. Bradberry, Paul S. Appelbaum, Natalie Gukasyan
7 citations
Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymethamphetamine (MDMA), emerged during the twentieth century and have likewise seen use in a broad range of settings. Interest has arisen in the use of classical psychedelics and entactogens, together termed "psychedelics," for therapeutic purposes in...
The American Journal of Bioethics
May 2, 2024
Edward Jacobs, Brian D. Earp, Paul S. Appelbaum et al.
29 citations
The first Hopkins-Oxford Psychedelic Ethics (HOPE) workshop convened to discuss ethical matters relating to psychedelics in August 2023 at the University of Oxford.The organizers (BDE, DBY, EJ) aim...
JAMA Psychiatry
April 10, 2024
Paul S. Appelbaum
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA...
Neuropharmacology
September 15, 2022
William R Smith, Paul S. Appelbaum
Classic psychedelics and related substances have shown promising initial research results. However, they raise a number of relatively novel ethical and policy challenges in light of their psychoactive properties, their emergence from the unregulated "underground" settings in which they have been used, their rapid commercialization, and the means and speed with which they are moving from...
Psychiatric Services
July 2022
Paul S. Appelbaum
Excited delirium, a diagnosis not found in the DSM and lacking clear criteria, has been used to explain fatalities of people in police custody, especially deaths of young Black men, and to exculpate police officers from responsibility. The label has also been invoked to justify the forceful restraint and sedation of people who may fail to obey the orders of law enforcement; ketamine, a...
JAMA
August 1, 2021
William R. Smith, Paul S. Appelbaum
60 citations
This Viewpoint reviews legalization initiatives for psychedelic substances and the concerns they raise by looking to the cautionary precedents involving the legalization and commercialization of other controlled substances.